Jonathan Leff, M.D. has been appointed vice president and chief medical officer, Halozyme Therapeutics. Dr. Leff was previously the vice president and global head of inflammation clinical development at Roche. He has experience in pharmaceutical product development from early stage molecules to global regulatory filing, approval and launch.

“Dr. Leff is a highly accomplished leader with a proven track record of successfully developing and commercializing large and small molecules across a broad range of therapeutic areas. I am delighted to welcome such a talented executive to Halozyme,” said Jonathan Lim, M.D., Halozyme’s president and chief executive officer. “This latest addition to the leadership team is indicative of Halozyme’s strong commitment and ability to attract some of the best and brightest talent in the biopharmaceutical industry.”

Dr. Leff managed the worldwide clinical development and registration for MabThera/Rituxan, ocrelizumab, and Actemra while at Roche. From 2002 to 2007, he was vice president, North American medical affairs, at Amgen, where he led a department of 500 professionals, and oversaw five therapeutic areas. From 1994 to 2002, Dr. Leff was at Merck, where he performed Phase I-IV research studies for Singulair.

Sign up today for Contracting & Outsourcing 2009!
www.contractpharma.com/2009conference